18F-FDG PET/CT Evaluation of Crizotinib and Lorlatinib Therapy in Metastatic ROS-1-Positive Non-Small Cell Lung Cancer.
Fiche publication
Date publication
janvier 2020
Journal
Clinical nuclear medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr PREVOST Alain
Tous les auteurs :
Dejust S, Moubtakir A, Prevost A, El Farsaoui K, Morland D
Lien Pubmed
Résumé
ROS-1-positive non-small cell lung cancers (NSCLCs) are rare (approximately 1% of all NSCLCs) and require a first-line treatment by crizotinib. Crizotinib resistance is frequent within the first 12 months of treatment. Lorlatinib is a novel tyrosine kinase inhibitor of ROS-1 recently indicated for metastatic or locally advanced crizotinib-resistant NSCLC. We report the use of lorlatinib as second-line with a complete tumoral response after only 3 months of treatment. This case shows the major role of F-FDG PET/CT in treatment evaluation and monitoring targeted therapy in metastatic NSCLC.
Référence
Clin Nucl Med. 2020 Jan 17;: